A carregar...
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case...
Na minha lista:
| Publicado no: | J Community Hosp Intern Med Perspect |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5906758/ https://ncbi.nlm.nih.gov/pubmed/29686796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20009666.2018.1454787 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|